Table 5.
Clusters of co-cited references in the field of sacubitril/valsartan research.
| Cluster ID | Size | Silhouette | Year | Main terms |
|---|---|---|---|---|
| #0 | 60 | 0.669 | 2012 | Heart failure; therapy; novel perspectives; system; natriuretic peptide degradation |
| #1 | 52 | 0.420 | 2018 | Heart failure; patients; Delphi consensus panel; readmission; care bundle |
| #2 | 40 | 0.605 | 2016 | Heart failure; physicians; regadenoson; adverse events; frequency |
| #3 | 26 | 0.730 | 2012 | Heart failure; ejection fraction; treatment; pathophysiology; advances |
| #5 | 14 | 0.974 | 2011 | Heart failure; ejection fraction; emerging drug strategies; emerging concepts; current understanding |
| #6 | 12 | 0.824 | 2012 | Heart failure; valsartan; latest evidence; place; therapy |
| #7 | 8 | 0.888 | 2017 | Valsartan; heart failure; implantable cardioverter-defibrillator use; sudden cardiac death; paradigm-hf analysis |
| #8 | 6 | 0.919 | 2017 | Heart failure; valsartan; atrial natriuretic peptide; treatment; reduced election fraction |